Congress funds cord blood banking—a quiet win for transplant patients
H.R. 5160 — Stem Cell Therapeutic and Research Reauthorization Act of 2025 · Filed by Chris Smith (R-NJ) · 21 cosponsors · Introduced Sep 4, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes federal funding for the C.W. Bill Young Cell Transplantation Program, which maintains a national inventory of cord blood units for medical transplants. It appropriates $31 million for 2026 and $33 million annually for 2027–2031, updates quality standards for stored cord blood, gives the Secretary of Health and Human Services authority to manage inventory based on scientific evidence, and allows transfer of units between qualified banks if one closes or fails to meet standards.
Why we flagged it
The bill's core function is straightforward: it reauthorizes and funds a federal cord blood banking program, updates its operational standards, and clarifies the Secretary's management authority. This is routine public-health legislation with no hidden mechanisms or narrow beneficiaries.
What the text implies
- Expanded Secretary discretion to manage inventory 'on Sec.'s own initiative' may allow de facto prioritization of certain genetic profiles or clinical uses without explicit statutory criteria, though framed as science-based.
- Authority to transfer cord blood units between banks if one becomes non-operational could consolidate inventory management among fewer providers, potentially affecting smaller cord blood banks' operational viability.
- Removal of 'in perpetuity' language from storage requirements may shorten the duration cord blood units are preserved, reducing long-term availability for future medical advances.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill funds a public health program that preserves life-saving medical resources (cord blood for transplants) and expands the Secretary's ability to manage inventory efficiently based on current science. Citizens gain access to a maintained national resource without new restrictions on their rights or remedies.
Who stands to gain
- Cord blood banking organizations and qualified cord blood banks (contract holders)
- Biopharmaceutical companies developing cell therapies (indirect: expanded inventory supports researc
Named in the bill
C.W. Bill Young Cell Transplantation Program, Stem Cell Therapeutic and Research Act of 2005, Public Health Service Act, Secretary of Health and Human Services, Food and Drug Administration, National Cord Blood Inventory, Cord blood banks
Where it stands
21 cosponsors: 11 Democrats, 10 Republicans.
- Sep 4, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 4, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
- May 13, 2026 — Markup held in committee · Congress.gov: “Subcommittee Consideration and Mark-up Session Held”
- May 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0”
- Jul 20, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)”
- Jul 20, 2026 — Floor vote scheduled · Congress.gov: “Mr. Guthrie moved to suspend the rules and pass the bill, as amended”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
5 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,050,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 78% of bills with at least one filing.
Chris Smith, the sponsor, reported $236,256 in PAC receipts in the 2026 cycle.
- National Marrow Donor Program — $580,000 on 2 filings
- Nmdp — $230,000 on 2 filings
- Astct — $140,000 on 2 filings
- New York Blood Center Enterprises — $90,000 on 1 filing
- Duke University Medical Center — $10,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,383 characters) on Jul 10, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress funds cord blood banking—a quiet win for transplant patients” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5160 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.